Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07524465 · ClinicalTrials.gov registry record · Phase 4
Mochida ReFeel for Digital Nerve Injuries
A Phase 4 study, sponsored by OrthoCarolina Research Institute.
- Not yet
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT07524465: Clinical Trial Phase 4 study, sponsored by OrthoCarolina Research Institute.
NCT07524465 is a Phase 4 study that has not yet begun recruiting, run by OrthoCarolina Research Institute. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07524465, a Phase 4 study, has not yet begun recruiting, sponsored by OrthoCarolina Research Institute.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an Investigator Led single-center, Prospective and Observational, Clinical Research Project. The specific aim of this study is to test/observe the safety and effectiveness of the ReFeel Device for Digital nerve injury in improving recovery time and outcomes. The primary objective of this study is to monitor clinical and surgical procedural outcomes for the use of ReFeel device.
Primary Outcome
Presented in millimetres and in ASSH designation (less than 6 mm 'normal', 6-10 mm 'fair', and 11 to 15 mm 'poor')
Interventions
- DEVICE ReFeel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
What is known before NCT07524465 opens enrollment
NCT07524465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which ReFeel is the first listed.
NCT07524465 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07524465 about?
NCT07524465 is a clinical study titled "Mochida ReFeel for Digital Nerve Injuries". This is an Investigator Led single-center, Prospective and Observational, Clinical Research Project. The specific aim of this study is to test/observe the safety and effectiveness of the ReFeel Device for Digital nerve injury in improving recovery time and outcomes. The primary objective of this stu...
What is the current status of trial NCT07524465?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2026-05-01. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07524465?
The interventions under investigation include: ReFeel (DEVICE).
Who is sponsoring clinical trial NCT07524465?
This trial is sponsored by OrthoCarolina Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07524465's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI